250 related articles for article (PubMed ID: 34594005)
1. Amplifying STING activation by cyclic dinucleotide-manganese particles for local and systemic cancer metalloimmunotherapy.
Sun X; Zhang Y; Li J; Park KS; Han K; Zhou X; Xu Y; Nam J; Xu J; Shi X; Wei L; Lei YL; Moon JJ
Nat Nanotechnol; 2021 Nov; 16(11):1260-1270. PubMed ID: 34594005
[TBL] [Abstract][Full Text] [Related]
2. Manganese Coordination Micelles That Activate Stimulator of Interferon Genes and Capture In Situ Tumor Antigens for Cancer Metalloimmunotherapy.
Li J; Ren H; Qiu Q; Yang X; Zhang J; Zhang C; Sun B; Lovell JF; Zhang Y
ACS Nano; 2022 Oct; 16(10):16909-16923. PubMed ID: 36200692
[TBL] [Abstract][Full Text] [Related]
3. Outer membrane vesicle-wrapped manganese nanoreactor for augmenting cancer metalloimmunotherapy through hypoxia attenuation and immune stimulation.
Luo S; Yang Y; Chen L; Kannan PR; Yang W; Zhang Y; Zhao R; Liu X; Li Y; Kong X
Acta Biomater; 2024 Jun; 181():402-414. PubMed ID: 38734282
[TBL] [Abstract][Full Text] [Related]
4. Manganese molybdate nanodots with dual amplification of STING activation for "cycle" treatment of metalloimmunotherapy.
Lei H; Li Q; Li G; Wang T; Lv X; Pei Z; Gao X; Yang N; Gong F; Yang Y; Hou G; Chen M; Ji J; Liu Z; Cheng L
Bioact Mater; 2024 Jan; 31():53-62. PubMed ID: 37601278
[TBL] [Abstract][Full Text] [Related]
5. Self-Assembled STING-Activating Coordination Nanoparticles for Cancer Immunotherapy and Vaccine Applications.
Sun X; Huang X; Park KS; Zhou X; Kennedy AA; Pretto CD; Wu Q; Wan Z; Xu Y; Gong W; Sexton JZ; Tai AW; Lei YL; Moon JJ
ACS Nano; 2024 Apr; 18(15):10439-10453. PubMed ID: 38567994
[TBL] [Abstract][Full Text] [Related]
6. Manganese is critical for antitumor immune responses via cGAS-STING and improves the efficacy of clinical immunotherapy.
Lv M; Chen M; Zhang R; Zhang W; Wang C; Zhang Y; Wei X; Guan Y; Liu J; Feng K; Jing M; Wang X; Liu YC; Mei Q; Han W; Jiang Z
Cell Res; 2020 Nov; 30(11):966-979. PubMed ID: 32839553
[TBL] [Abstract][Full Text] [Related]
7. Endosomolytic polymersomes increase the activity of cyclic dinucleotide STING agonists to enhance cancer immunotherapy.
Shae D; Becker KW; Christov P; Yun DS; Lytton-Jean AKR; Sevimli S; Ascano M; Kelley M; Johnson DB; Balko JM; Wilson JT
Nat Nanotechnol; 2019 Mar; 14(3):269-278. PubMed ID: 30664751
[TBL] [Abstract][Full Text] [Related]
8. Manganese-Based Immunostimulatory Metal-Organic Framework Activates the cGAS-STING Pathway for Cancer Metalloimmunotherapy.
Zheng SJ; Yang M; Luo JQ; Liu R; Song J; Chen Y; Du JZ
ACS Nano; 2023 Aug; 17(16):15905-15917. PubMed ID: 37565626
[TBL] [Abstract][Full Text] [Related]
9. Gas-Amplified Metalloimmunotherapy with Dual Activation of Pyroptosis and the STING Pathway for Remodeling the Immunosuppressive Cervical Cancer Microenvironment.
Liu L; Lei H; Hou G; Zhang L; Chen Y; Lu Y; Pei Z; Ge J; Wu J; Zhou J; Cheng L
ACS Nano; 2024 May; 18(20):12830-12844. PubMed ID: 38709246
[TBL] [Abstract][Full Text] [Related]
10. Identification of Novel Carbocyclic Pyrimidine Cyclic Dinucleotide STING Agonists for Antitumor Immunotherapy Using Systemic Intravenous Route.
Vyskocil S; Cardin D; Ciavarri J; Conlon J; Cullis C; England D; Gershman R; Gigstad K; Gipson K; Gould A; Greenspan P; Griffin R; Gulavita N; Harrison S; Hu Z; Hu Y; Hata A; Huang J; Huang SC; Janowick D; Jones M; Kolev V; Langston SP; Lee HM; Li G; Lok D; Ma L; Mai D; Malley J; Matsuda A; Mizutani H; Mizutani M; Molchanova N; Nunes E; Pusalkar S; Renou C; Rowland S; Sato Y; Shaw M; Shen L; Shi Z; Skene R; Soucy F; Stroud S; Xu H; Xu T; Abu-Yousif AO; Zhang J
J Med Chem; 2021 May; 64(10):6902-6923. PubMed ID: 34000802
[TBL] [Abstract][Full Text] [Related]
11. Metal coordination nanotheranostics mediated by nucleoside metabolic inhibitors potentiate STING pathway activation for cancer metalloimmunotherapy.
Yang L; Wang Y; Song Y; Li Z; Lei L; Li H; He B; Cao J; Gao H
J Control Release; 2024 May; 370():354-366. PubMed ID: 38685387
[TBL] [Abstract][Full Text] [Related]
12. Supramolecular Cyclic Dinucleotide Nanoparticles for STING-Mediated Cancer Immunotherapy.
Xu L; Deng H; Wu L; Wang D; Shi L; Qian Q; Huang X; Zhu L; Gao X; Yang J; Su Y; Feng J; Zhu X
ACS Nano; 2023 Jun; 17(11):10090-10103. PubMed ID: 37253192
[TBL] [Abstract][Full Text] [Related]
13. STING-activating cyclic dinucleotide-manganese nanoparticles evoke robust immunity against acute myeloid leukemia.
Aikins ME; Sun X; Dobson H; Zhou X; Xu Y; Lei YL; Moon JJ
J Control Release; 2024 Apr; 368():768-779. PubMed ID: 38492861
[TBL] [Abstract][Full Text] [Related]
14. Biodegradable STING agonist nanoparticles for enhanced cancer immunotherapy.
Wilson DR; Sen R; Sunshine JC; Pardoll DM; Green JJ; Kim YJ
Nanomedicine; 2018 Feb; 14(2):237-246. PubMed ID: 29127039
[TBL] [Abstract][Full Text] [Related]
15. TNFα and Radioresistant Stromal Cells Are Essential for Therapeutic Efficacy of Cyclic Dinucleotide STING Agonists in Nonimmunogenic Tumors.
Francica BJ; Ghasemzadeh A; Desbien AL; Theodros D; Sivick KE; Reiner GL; Hix Glickman L; Marciscano AE; Sharabi AB; Leong ML; McWhirter SM; Dubensky TW; Pardoll DM; Drake CG
Cancer Immunol Res; 2018 Apr; 6(4):422-433. PubMed ID: 29472271
[TBL] [Abstract][Full Text] [Related]
16. Metalloimmunology: The metal ion-controlled immunity.
Wang C; Zhang R; Wei X; Lv M; Jiang Z
Adv Immunol; 2020; 145():187-241. PubMed ID: 32081198
[TBL] [Abstract][Full Text] [Related]
17. STING agonist delivery by tumour-penetrating PEG-lipid nanodiscs primes robust anticancer immunity.
Dane EL; Belessiotis-Richards A; Backlund C; Wang J; Hidaka K; Milling LE; Bhagchandani S; Melo MB; Wu S; Li N; Donahue N; Ni K; Ma L; Okaniwa M; Stevens MM; Alexander-Katz A; Irvine DJ
Nat Mater; 2022 Jun; 21(6):710-720. PubMed ID: 35606429
[TBL] [Abstract][Full Text] [Related]
18. Current patent and clinical status of stimulator of interferon genes (STING) agonists for cancer immunotherapy.
Marloye M; Lawler SE; Berger G
Pharm Pat Anal; 2019 Jul; 8(4):87-90. PubMed ID: 31354104
[No Abstract] [Full Text] [Related]
19. Lanthanide-Nucleotide Coordination Nanoparticles for STING Activation.
Luo Z; Liang X; He T; Qin X; Li X; Li Y; Li L; Loh XJ; Gong C; Liu X
J Am Chem Soc; 2022 Sep; 144(36):16366-16377. PubMed ID: 36037283
[TBL] [Abstract][Full Text] [Related]
20. Discovery of BI 7446: A Potent Cyclic Dinucleotide STING Agonist with Broad-Spectrum Variant Activity for the Treatment of Cancer.
Kuttruff CA; Fleck M; Carotta S; Arnhof H; Bretschneider T; Dahmann G; Gremel G; Grube A; Handschuh S; Heimann A; Hofmann MH; Impagnatiello MA; Nar H; Rast G; Schaaf O; Schmidt E; Oost T
J Med Chem; 2023 Jul; 66(14):9376-9400. PubMed ID: 37450324
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
